# A Rare Case of Rhizomucor pusillus Infection in a 3-Year-Old Child with Acute Lymphoblastic Leukemia, Presenting with Lung and Brain Abscesses—Case Report

**Authors:** Yanko Pahnev, Boryana Avramova, Natalia Gabrovska, Yolin Dontcheva, Genoveva Tacheva, Krasimir Minkin, Hans Kreipe, Nadezhda Yurukova, Marin Penkov, Nikola Kartulev, Zdravka Antonova, Velichka Oparanova, Nadezhda Tolekova, Petia Moutaftchieva, Bogdan Mladenov, Plamena Hristova, Kaloyan Gabrovski, Svetlana Velizarova, Albena Spasova, Hristo Shivachev

PMC · DOI: 10.3390/idr18010002 · Infectious Disease Reports · 2025-12-23

## TL;DR

A 3-year-old child with leukemia developed a rare fungal infection affecting the lungs and brain, but recovered well after surgery and treatment.

## Contribution

This case report highlights a rare Rhizomucor pusillus infection in a young leukemia patient with lung and brain abscesses.

## Key findings

- The patient showed no recurrence of the infection after two years of follow-up.
- Surgical debridement and antifungal therapy led to successful recovery.
- Rhizomucor pusillus infections are rare but can affect multiple organs in immunocompromised children.

## Abstract

Invasive Mucormycosis (IM) is an extremely rare infection with a high mortality rate, caused by a group of fungi classified as Mucorales moulds. Rhizomucor pusillus is a saprophitic, thermophilic, and angioinvasive microorganism that grows and lives at about 45 °C and is usually found in different environmental spaces such as soil, air, water, food, and other organic matter. These features predispose the infection to wide dissemination, especially in immunocompromised patients and most often in children after chemotherapy for hematological malignancies (HMs). Mucormycosis in patients with hematologic malignancies and neutropenia represents between 0.07% and 4.29% of the concomitant diseases. IM can develop into an infection in different sites, but its most common manifestation is pulmonary, followed by rhino-orbital–cerebral and disseminated forms. In recent years, an increased morbidity rate has been associated with the ongoing COVID-19 pandemic, as cited in the literature. There are many publications with COVID-19-associated mucormycosis (CAM) cases. The present treatment protocol includes extensive and radical surgical debridement and systemic antifungal therapy with Liposomal Amphotericin B (L-AmB), Posaconazole, and Isavuconazole, either combined or as monotherapy. Despite these new treatment modalities, the mortality rate remains over 50%. We present a rare case of a 3-year-old child with acute lymphoblastic leukemia (ALL) and systemic Rhizomucor pusillus infection, diagnosed on the occasion of lung and brain abscesses. The patient underwent lung and brain surgery and is recovering well with no further complications. The two-year follow-up period shows no signs of recurrence of the disease.

## Linked entities

- **Chemicals:** Liposomal Amphotericin B (PubChem CID 44405442), Posaconazole (PubChem CID 468595), Isavuconazole (PubChem CID 6918485)
- **Diseases:** Acute Lymphoblastic Leukemia (MONDO:0004967), Mucormycosis (MONDO:0019136), neutropenia (MONDO:0001475)

## Full-text entities

- **Diseases:** ALL (MESH:D054198), HMs (MESH:D019337), Rhizomucor pusillus (MESH:C000656949), CAM (MESH:D000086382), neutropenia (MESH:D009503), IM (MESH:D009091), Lung and Brain Abscesses (MESH:D008169), infection (MESH:D007239)
- **Chemicals:** Amphotericin B (MESH:D000666), Isavuconazole (MESH:C508735), L-AmB (MESH:C068538), Posaconazole (MESH:C101425)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12821471/full.md

## Figures

14 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12821471/full.md

## References

27 references — full list in the complete paper: https://tomesphere.com/paper/PMC12821471/full.md

---
Source: https://tomesphere.com/paper/PMC12821471